Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EPS (Weighted Average and Diluted) (2019 - 2025)

Historic EPS (Weighted Average and Diluted) for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$1.1.

  • Beam Therapeutics' EPS (Weighted Average and Diluted) rose 598.29% to -$1.1 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.43, marking a year-over-year decrease of 18037.97%. This contributed to the annual value of -$4.58 for FY2024, which is 16610.14% down from last year.
  • Beam Therapeutics' EPS (Weighted Average and Diluted) amounted to -$1.1 in Q3 2025, which was up 598.29% from -$1.0 recorded in Q2 2025.
  • Beam Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $1.91 for Q4 2023, and its period low was -$3.35 during Q1 2021.
  • For the 5-year period, Beam Therapeutics' EPS (Weighted Average and Diluted) averaged around -$1.04, with its median value being -$1.1 (2025).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 27142.86% in 2022, then surged by 45370.37% in 2023.
  • Over the past 5 years, Beam Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.91 in 2021, then skyrocketed by 40.66% to -$0.54 in 2022, then surged by 453.7% to $1.91 in 2023, then crashed by 157.47% to -$1.1 in 2024, then decreased by 0.21% to -$1.1 in 2025.
  • Its last three reported values are -$1.1 in Q3 2025, -$1.0 for Q2 2025, and -$1.24 during Q1 2025.